Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gene Therapy Trial Shows Promise for Type of Blindness

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Patients showed improvements in their vision in dim light and two of the six were able to read more lines on the eye chart.

The first clinical trial of a gene therapy for an inherited cause of progressive blindness called choroideremia has shown very promising initial results which have surpassed expectations of the Oxford University researchers leading the study.

The aim of the study was to get the gene therapy into the cells in the retina of the eye without causing damage. After six months, however, the patients actually showed improvements in their vision in dim light and two of the six were able to read more lines on the eye chart.

A total of nine patients have now had one eye treated with the gene therapy in operations at the Oxford Eye Hospital, part of the Oxford University Hospitals NHS Trust. The therapy is given in one eye to allow comparison with progression of the disease in the other eye.

The first patient to be treated, Jonathan Wyatt, 65, says: ‘My left eye, which had always been the weaker one, was that which was treated as part of this trial...Now when I watch a football match on the TV, if I look at the screen with my left eye alone, it is as if someone has switched on the floodlights. The green of the pitch is brighter, and the numbers on the shirts are much clearer.’

Professor Robert MacLaren of the Nuffield Laboratory of Ophthalmology at the University of Oxford led the development of the retinal gene therapy and this first clinical trial. He says: ‘It is still too early to know if the gene therapy treatment will last indefinitely, but we can say that the vision improvements have been maintained for as long as we have been following up the patients, which is two years in one case.'

The clinical trial is funded by the Health Innovation Challenge Fund, a partnership between the Wellcome Trust and the Department of Health.

Results at six months are now reported for the first six patients in The Lancet medical journal.

Professor MacLaren, who is also a consultant surgeon at the Oxford Eye Hospital and honorary consultant at Moorfields Eye Hospital, says: ‘The results showing improvement in vision in the first six patients confirm that the virus can deliver its DNA payload without causing significant damage to the retina.

'This has huge implications for anyone with a genetic retinal disease such as age-related macular degeneration or retinitis pigmentosa, because it has for the first time shown that gene therapy can be applied safely before the onset of vision loss.’

Based on the success of the treatment in the first six patients, three more have recently been tested at a higher dose.

Wayne Thompson, 43, an IT project manager in Staffordshire, was treated in April as part of the subsequent trial: ‘One night in the summer, my wife called me outside as it was a particularly starry evening. As I looked up, I was amazed that I was able to see a few stars. I hadn’t seen stars for a long, long time...For a long time I lived with the certainty of losing vision. Now I have uncertainty of whether the trial will work, but it is worth the risk.’

Choroideremia is a rare inherited cause of blindness that affects around 1 in 50,000 people. The first signs tend to be seen in boys in late childhood, with the disease slowly progressing until vision is lost. There is currently no cure. It is caused by defects in the CHM gene on the X chromosome, which explains why it is almost always boys that are affected. Without the protein produced by the CHM gene, pigment cells in the retina of the eye slowly stop working, then die off. As the disease progresses, the surviving retina gradually shrinks in size, reducing vision.

The gene therapy approach uses a small, safe virus to carry the missing CHM gene into the light-sensing cells in the retina. In an operation similar to cataract surgery, the patient’s retina is first detached and then the virus is injected underneath using a very fine needle.

The aim is for the CHM gene, once delivered into the cells of the retina, to start producing protein and stop the cells dying off. ‘If we were able to treat people early, get them in their teens or late childhood, we’d be getting the virus in before their vision is lost,’ explains Professor MacLaren. ‘If the treatment works, we would be able to prevent them from going blind.’

The research has also received support from the National Institute for Health Research Oxford Biomedical Research Centre and the charity Fight for Sight, the main UK charity that funds pioneering eye research to prevent sight loss and treat eye disease.

Professor Miguel Seabra, whose research at Imperial College London identified the protein involved in choroideremia, says: ‘My team has spent 20 years trying to understand choroideraemia and develop a cure, so to finally see the rewards reaching patients is extremely gratifying, both for us and the families who supported our research.’

The Phase I trial began with six patients: two with excellent visual acuity, two with good acuity and two with reduced acuity. Visual acuity is the acuteness or clearness of vision, and is measured by reading lines of letters on a sight chart.

Six months after the operation, those with excellent or good acuity had the same level of acuity they began with, but could see more in the dark when tested – despite the detachment of the retina during the operation.

The two patients with reduced acuity saw improvements in their vision, being able to read two and four more lines on the sight chart. One of these, Jonathan Wyatt, a barrister from Bristol, was the first patient to be treated. He has shown sustained improvement in visual acuity for two years. Toby Stroh, a solicitor in London, has shown continued improvement at one year.

Professor MacLaren says: ‘What’s really exciting is that the improvement in these two patients at six months is significant and it has so far been maintained.

‘I am incredibly excited to see what will happen. The difficult bits are done: we know the virus carrying the gene therapy gets into the cells and the retina recovers after the surgery. Now it’s just waiting to see how the patients progress.’

Patients have come from Moorfields Eye Hospital, the Manchester Royal Eye Hospital and the University of Southampton.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford Spinout Raises £10m For Precision System To Treat Disease
Oxford spinout EvOx Therapeutics will harness the body's own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable – including those affecting the brain, as well as autoimmune diseases and cancers.
Wednesday, May 11, 2016
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Thursday, October 08, 2015
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Friday, October 02, 2015
A Combination Of Genes Results In Malaria Drug Resistance
The largest genome-wide study of the malaria parasite finds that the drug resistance occurs because of a key mutation happening on top of 'background' mutations which make the parasite more likely to develop drug resistance later.
Tuesday, January 20, 2015
Neanderthal Viruses Found in Modern Humans
Ancient viruses from Neanderthals have been found in modern human DNA by researchers at Oxford University and Plymouth University.
Tuesday, November 19, 2013
New Gene Discovered in Human Stem Cells may Benefit Transplant Patients
Oxford scientists have uncovered that the gene Nephroblastoma Overexpressed plays a key role in regulating the production of blood from stem cells.
Tuesday, May 01, 2007
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!